Company intelligence / Profile preview

CellxLife

Los Angeles, California, United Statescellxlife.com ↗

Ownership: Private
Development stage: Phase 1

Overview

In Phase I trials, 75% of children with metastatic osteosarcoma who responded well to surgery overcame their cancer and are still alive today. 62.5% of all children with metastatic osteosarcoma treated with the therapy lived for over 15 years, compared to typical 5-year survival rates of less than 20%.[1]

Therapeutic areas: Oncology
Modalities: Dendritic cell-based therapeutic vaccine
Industry: Biotech

Drug pipeline

1 asset

CellxLife DC Vaccine

Unknown

Beyond the preview

Go deeper on CellxLife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellxLife.

Explore the full profile